Satellos Bioscience Inc.
MSCLFDrugs in Pipeline
1
Phase 3 Programs
0
Upcoming Catalysts
1
Next Catalyst
Q1 2027
Market Overview
Stock performance and key metrics
1 upcoming, 0 past
| Drug Name | Phase | Indication | Designations | Patent |
|---|---|---|---|---|
SAT-3247 | Phase 2 | Duchenne Muscular Dystrophy | - | - |
Full breakdown — the signals behind the verdict
Frequently asked questions
What is in Satellos Bioscience Inc.'s drug pipeline?→
CatalystAlert tracks 1 drug candidate in Satellos Bioscience Inc.'s (MSCLF) pipeline across Phase 2. Its lead program is SAT-3247 (Phase 2). Each drug's phase, indication and upcoming catalysts are listed on this page.
When is Satellos Bioscience Inc.'s next FDA catalyst?→
Satellos Bioscience Inc.'s (MSCLF) next tracked catalyst is a Phase 2 expected March 31, 2027. See the catalyst timeline on this page for the full schedule of PDUFA dates, trial readouts and FDA events.
How do I track MSCLF biotech catalysts?→
Add MSCLF to your CatalystAlert watchlist for alerts ahead of each catalyst, and follow Satellos Bioscience Inc.'s live catalyst calendar, drug pipeline and clinical-trial timeline on this page — sourced from ClinicalTrials.gov, FDA and SEC filings.